NCT01059786 · OUTCOME

Overall Survival

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia · Source last updated 2026-07-22

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: time between the first day of treatment to the day of death

What was measured

OS is the time between the first day of treatment to the day of death.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2031-06
denom Units Selected: Participants
description: OS is the time between the first day of treatment to the day of death.
reporting Status: NOT_POSTED
time Frame: time between the first day of treatment to the day of death
title: Overall Survival
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice